Acute telogen effluvium associated with SARS-CoV-2 infection

Dominguez‐Santás, Miguel; Haya-Martínez, Lara; Fernández‐Nieto, Diego; ­Jimenez‐Cauhe, Juan; Suárez‐Valle, Ana; Díaz‐Guimaraens, Borja

doi:10.31128/ajgp-covid-32

Cited by 28 publications

(36 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This was a single health system, retrospective study with a relatively small sample size. However, to our knowledge, the only other studies investigating TE triggered by COVID‐19 infection are case reports and one 10‐patient case series 8,9 . The case series published by Mieczkowska et al included four White patients, one Black patient, and four patients of unknown race 8 .…”

Section: Discussionmentioning

confidence: 99%

“…However, to our knowledge, the only other studies investigating TE triggered by COVID-19 infection are case reports and one 10-patient case series. 8,9 The case series published by Mieczkowska In addition, TE caused by hydroxychloroquine, azithromycin, or other medications cannot be ruled out. The global pandemic itself is another potential source of psychosocial stress, and there may be an overall increase in the incidence of TE as a result.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Telogen effluvium associated with COVID‐19 infection

Olds

Liu

Luk

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

Telogen effluvium (TE) is characterized by diffuse hair shedding 2‐3 months after a stressor, and COVID‐19 infection is potentially one such stressor. Those who were infected with the virus were under immense psychosocial and physiologic stress. We retrospectively reviewed electronic medical records of 552 patients who were evaluated by a Henry Ford Health System dermatologist between February 2020 and September 2020 and had a diagnosis of COVID‐19 infection. Ten patients were identified with TE attributed to COVID‐19 infection and described their presentations as a case series. For the ten patients selected, the mean age was 48.5 years old and 90% were female. Six of the patients were Black, one Middle Eastern, and three White. On average, the hair shedding began 50 days after the first symptom of COVID‐19 infection. About 80% of these patients were treated with antibiotics, systemic corticosteroids, and/or hydroxychloroquine for their COVID‐19 infection and 70% were hospitalized. The presentations of these patients suggest that COVID‐19 infection may be a significant trigger of TE. TE caused by hydroxychloroquine, azithromycin or other medications cannot be ruled out, and the global pandemic itself is a source of psychosocial stress. Further studies will be needed to understand the long‐term prevalence and prognosis of TE associated with COVID‐19 infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Telogen effluvium associated with COVID‐19 infection

Olds

Liu

Luk

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…This topic was discussed in November 2020 at the 94th SIDEMAST Congress in Italy with an estimation of the incidence of hair loss in subjects with COVID-19 of about 30%. In particular, in about 90% of cases, hair loss is reported to occur after 2 or 3 months of healing, mainly in the form of acute telogen effluvium [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Italian Survey for the Evaluation of the Effects of Coronavirus Disease 2019 (COVID-19) Pandemic on Alopecia Areata Recurrence

Rinaldi¹,

Trink²,

Giuliani³

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: The inflammation storm involved in coronavirus disease 2019 (COVID-19) infection and worsening and the psychological stress derived from current quarantine conditions can affect the course of many skin and scalp conditions. This study examined the possible effects of COVID-19 on alopecia areata (AA) relapse in patients suffering from these scalp conditions during the pandemic. Methods: The study was carried out in the form of an observational cross-sectional type using a questionnaire sent by mail to a cohort of patients affected by AA during the pandemic from March 2020 to October 2020. Results: During the pandemic, AA relapse was reported in 42.5% of the participants who also declared COVID-19 infection, confirmed by nasopharyngeal swab or hematological analysis. The relapse was reported about 2 months later COVID-19 infection (median of 2.14 months) and 74.0% of these participants continue to experience AA symptoms when the survey was proposed. Only 12.5% of participants reported AA relapse in the absence of COVID-19 infection. Conclusions: The present study reported a significant relapse in patients suffering from AA and infected by COVID-19. This phenomenon could be attributed to the inflammation storm typical of COVID-19 infection and the psychological stress derived from quarantine conditions.

show abstract

“…So far, single case reports of dystrophic anagen 4 and of telogen effluvium 5 in association with COVID‐19 exist, though the former was not confirmed by light microscopic examination of the hair. In the latter, the trichogram was consistent with telogen effluvium.…”

Section: Patient No Sex/age Pre‐existing Hair Condition Fever Anosmiamentioning

confidence: 98%

What can the hair tell us about COVID‐19?

Trüeb

Rezende²,

Dias

2020

Experimental Dermatology

View full text Add to dashboard Cite

The novel viral pandemic coronavirus disease 2019 (COVID‐19) has sparked uncertainties as to its origin, epidemiology and natural course. The study of the cutaneous manifestations of COVID‐19 has evolved with the hope that they may be useful as markers for the disease, prognostication and pathogenic insights into the disease. With regard to the hair, clinicopathological correlations have remained elusive. More recently, androgenetic alopecia and grey hair have been proposed as cutaneous markers for elevated severity risk. So far, we have only observed postinfectious effluvium in a causal association with COVID‐19. The onset and acuity of hair shedding depended on the clinical severity of disease. There was complete recovery of hair.

show abstract

Acute telogen effluvium associated with SARS-CoV-2 infection

Cited by 28 publications

References 4 publications

Telogen effluvium associated with COVID‐19 infection

Telogen effluvium associated with COVID‐19 infection

Italian Survey for the Evaluation of the Effects of Coronavirus Disease 2019 (COVID-19) Pandemic on Alopecia Areata Recurrence

What can the hair tell us about COVID‐19?

Contact Info

Product

Resources

About